What is Tesofensine (non-peptide)?

An oral triple reuptake inhibitor (serotonin, norepinephrine, dopamine).

Tesofensine (non-peptide) in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

11 registered trials · 10 indexed papers · 25 human / 11 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

An oral triple reuptake inhibitor (serotonin, norepinephrine, dopamine). The name is garbled in the captions.

Registered human trials (11)

Trial	Phase	Status	Year	Enrolled
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)	Phase 2	withdrawn	2021
Study of Tesomet With Open-label Extension in Subjects With Prader-Willi Syndrome	Phase 2	withdrawn	2021
48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)	Phase 2	completed	2019	21
Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)	Phase 2	completed	2017	18
Study to Investigate the Pharmacokinetic Profile	Phase 1	completed	2017	60
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus	Phase 2	completed	2016	60
Evaluation of Long Term Safety of Tesofensine in Patients With Obesity	Phase 2	completed	2007	140
Effect of Tesofensine on Energy Balance in Humans.	Phase 1/Phase 2	completed	2007	32
Effect of Tesofensine on Weight Reduction in Patients With Obesity.	Phase 2	completed	2006	200
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) ([amount hidden]) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations	Phase 2	completed	2003	254
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type	Phase 2	completed	2003	430

Peer-reviewed studies (10)

Paper	Authors	Journal	Year	Type
The effect of tesofensine on appetite sensations	Gilbert JA et al.	Obesity (Silver Spring, Md.)	2012	Randomized Controlled Trial
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users	Schoedel KA et al.	Clinical pharmacology and therapeutics	2010	Randomized Controlled Trial
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men	Sjödin A et al.	International journal of obesity (2005)	2010	Randomized Controlled Trial
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine	Lehr T et al.	The AAPS journal	2010	Randomized Controlled Trial
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]	Nielsen AL et al.	Ugeskrift for laeger	2009	Randomized Controlled Trial
A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam	Lehr T et al.	Clinical pharmacokinetics	2009	Randomized Controlled Trial
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial	Astrup A et al.	Lancet (London, England)	2008	Randomized Controlled Trial
Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study	Rascol O et al.	Archives of neurology	2008	Randomized Controlled Trial
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease	Lehr T et al.	British journal of clinical pharmacology	2007	Randomized Controlled Trial
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease	Hauser RA et al.	Movement disorders : official journal of the Movement Disorder Society	2007	Randomized Controlled Trial

More cited research

Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine (2026, human observational)
Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET (2014, human observational)
Under-reporting of adverse effects of tesofensine (2013, human observational)
Tesofensine and weight loss (2009, human observational)
Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons (2024, animal)
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats (2013, animal)
Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat (2013, animal)
Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats (2012, animal)

Conditions researched

Related compounds

FAQ

What is Tesofensine (non-peptide)?

An oral triple reuptake inhibitor (serotonin, norepinephrine, dopamine).

How many registered human trials study Tesofensine (non-peptide)?

The PeptideWhiz trial index lists 11 registered trials for Tesofensine (non-peptide), the most recent from 2021.

How much published research exists on Tesofensine (non-peptide)?

The PeptideWhiz paper index links 10 PubMed papers to Tesofensine (non-peptide); by study type, 25 human and 11 animal studies.

Which conditions is Tesofensine (non-peptide) researched for?

Fat loss, obesity & body recomposition, Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Dementia, Alzheimer's & cognitive decline, Insulin resistance, prediabetes & type 2 diabetes, Parkinson's disease.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research